Intest Res.  2016 Apr;14(2):107-108. 10.5217/ir.2016.14.2.107.

Concerns in pregnancy and childbirth of women with inflammatory bowel disease

• Jung SA

• KMID: 2425281
• DOI: http://doi.org/10.5217/ir.2016.14.2.107

Abstract

No abstract available.

MeSH Terms

Female
Humans
Inflammatory Bowel Diseases*
Parturition*
Pregnancy*

Reference

1. Mahadevan U, Matro R. Care of the pregnant patient with inflammatory bowel disease. Obstet Gynecol. 2015; 126:401–412. PMID: 26241432.

2. Gisbert JP, Chaparro M. Safety of anti-TNF agents during pregnancy and breastfeeding in women with inflammatory bowel disease. Am J Gastroenterol. 2013; 108:1426–1438. PMID: 23752881.

3. Androulakis I, Zavos C, Christopoulos P, Mastorakos G, Gazouli M. Safety of anti-tumor necrosis factor therapy during pregnancy in patients with inflammatory bowel disease. World J Gastroenterol. 2015; 21:13205–13211. PMID: 26715803.

4. Guiddir T, Frémond ML, Triki TB, et al. Anti-TNF-α therapy may cause neonatal neutropenia. Pediatrics. 2014; 134:e1189–e1193. PMID: 25266439.

5. de Meij TG, Jharap B, Kneepkens CM, et al. Long-term follow-up of children exposed intrauterine to maternal thiopurine therapy during pregnancy in females with inflammatory bowel disease. Aliment Pharmacol Ther. 2013; 38:38–43. PMID: 23675854.

6. Akbari M, Shah S, Velayos FS, Mahadevan U, Cheifetz AS. Systematic review and meta-analysis on the effects of thiopurines on birth outcomes from female and male patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013; 19:15–22. PMID: 22434610.

7. Komoto S, Motoya S, Nishiwaki Y, et al. Pregnancy outcome in women with inflammatory bowel disease treated with anti-tumor necrosis factor and/or thiopurine therapy: a multicenter study from Japan. Intest Res. 2016; 14:139–145.